Unfortunately, the subsequent randomized Phase III trial showed no significant OS increase in patients with advanced HCC and high c-Met expression treated with sorafenib compared to a placebo (NCT01755767), compromising the possibility of further development for clinical use. This evidence concerns the gene MET and hepatocellular carcinoma.